FOLFOX 4

DRUG3 trials

Sponsors

Sanofi, Amgen Research (Munich) GmbH, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions

Colorectal CancerEsophageal NeoplasmsLiver MetastasesStomach Neoplasms

Phase 2

Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer

CompletedNCT00160030

SanofiEsophageal Neoplasms

Start: 2004-09-30Updated: 2009-12-07

Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

CompletedNCT00866944

Amgen Research (Munich) GmbHColorectal Cancer, Liver Metastases

Start: 2009-03-31End: 2011-11-30Updated: 2011-11-11

Phase 3

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoStomach Neoplasms

Start: 2016-12-31End: 2021-12-31Target: 280Updated: 2021-09-13

Related Papers

Health-related quality of life (HRQoL) with paclitaxel plus ramucirumab (PTX-RAM) switch maintenance versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: A secondary endpoint of the ARMANI phase 3 randomized trial.

Journal of Clinical Oncology2025-05-281 citations

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.

2024-11-1516 citations

Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.

Journal of Clinical Oncology2024-06-055 citations

Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.

Journal of Clinical Oncology2019-05-20

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

2019-03-2912 citations